Smellprints in lung Cancer; the role of ENose in diagnosis and Treatment (SCENT): part 4. Diagnostic value of the eNose in Head and Neck Cancer

Smellprints in lung Cancer; the role of ENose in diagnosis and Treatment (SCENT): part 4. Diagnostic value of the eNose in Head and Neck Cancer - eNose in head neck cancer/SCENT study, part 4

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34633

Enrollment

Registered

2010-04-06

Start date

2010-05-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head neck cancer oropharyngeal carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Written informed consent obtained. Head and neck cancer: • adult 18-8o years • head and neck cancer of oral and pharyngeal area • Histology: squamous cell carcinoma controls: Matched for: • Age: 3 months B. current smoker or ex-smoker

Exclusion criteria

Exclusion criteria: consumption of alcohol in last 48 hours prior to the test. severe paradontitis • any infection (especially of the airways) in the last 4 weeks • Other known pulmonary disease • Other or former malignancy • Diabetes mellitus (documented in the past) • Pregnancy • Untreated hypercholesterolaemia (documented in the past) • Significant cardiovascular disease (documented in the past) eating (including chewing gum), drinking, smoking

Design outcomes

Primary

Measure	Time frame
primary outcome parameter is the difference in breathprints provided by the electronic nose	—

Countries

Netherlands

Outcome results